2030 roadmap: customized cell therapy for all US patients
One plausible path for approved, customized stem cell therapies to move beyond specialist centers by 2030, and the conditions it depends on.
Build the evidence base
More cell and gene therapy approvals under FDA's flexible CMC approach and expedited programs. Academic and industry sponsors file INDs for customized stem cell products.
Prove distributed manufacturing
Sponsors show that hub-and-spoke or point-of-care manufacturing gives comparable product quality across sites, inside their INDs and BLAs.
Qualified treatment networks
Approved products reach networks of certified centers (as CAR-T did through qualified treatment centers), with standard training, data capture and long-term follow-up.
Community and urgent care roles
Urgent care and community clinics act as access points: screening and referral, sample collection where a label allows, follow-up visits, and real-world data. Administering a product would depend on each product's label and any REMS.
What has to be true
- Products approved by BLA, with labels that allow administration outside specialist centers
- Validated, automated closed-system manufacturing with reliable potency assays
- Payer coverage and reimbursement models for one-time, high-cost therapies
- Trained staff, cold-chain logistics and adverse-event management at community sites
- Interoperable registries and AI-assisted real-world evidence for long-term safety follow-up